Brief: NeuroMetrix Receives FDA Breakthrough Device Designation For Treatment Of Chronic Chemotherapy Induced Peripheral Neuropathy

NeuroMetrix

18/01/2022 14:29

Jan 18 (Reuters) - NeuroMetrix Inc  NURO.O :
    * NEUROMETRIX RECEIVES FDA BREAKTHROUGH DEVICE DESIGNATION
FOR
TREATMENT OF CHRONIC CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY
(CIPN) WITH ITS WEARABLE NEUROSTIMULATION TECHNOLOGY
    * NEUROMETRIX -FDA WILL PROVIDE NEUROMETRIX WITH PRIORITY
REVIEW
AND INTERACTIVE COMMUNICATION REGARDING DEVICE
DEVELOPMENT,THROUGH TO COMMERCIALIZATION
    * NEUROMETRIX INC - USE OF QUELL FOR CHEMOTHERAPY INDUCED
PERIPHERAL NEUROPATHY IS INVESTIGATIONAL AND HAS NOT BEEN
CLEARED OR APPROVED BY FDA
    * NEUROMETRIX INC - SAFETY AND EFFECTIVENESS OF QUELL FOR
THIS
PURPOSE HAVE NOT BEEN REVIEWED BY FDA

Source text for Eikon:  ID:nGNX1WBYnZ 
Further company coverage:  NURO.O 

 ((Reuters.Briefs@thomsonreuters.com;))